Read the full release with references in PDF

Boston, US, 4 April 2016 - Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016). The three-year part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline) data demonstrated that 160 weeks of treatment with Saxenda® (liraglutide 3 mg) (n=1,505) in combination with a reduced-calorie diet and increased physical activity resulted in significant improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with placebo (reduced-calorie diet and increased physical activity alone) (n=749).1

Further information

Media:    
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Åsa Josefsson +45 3079 7708 aajf@novonordisk.com 
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com 
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com 
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com 
Kasper Veje +45 3079 8519 kpvj@novonordisk.com